Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Jacobio Pharmaceuticals presented promising preliminary Phase I clinical trial data for its BET inhibitor JAB-8263 at the American Society of Hematology Annual Meeting. The drug showed positive results in reducing spleen volume and symptom scores in myelofibrosis patients. This development highlights Jacobio’s innovative approach in the competitive pharmaceutical landscape.
For further insights into HK:1167 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Disney+ (NYSE:DIS) Hits Disney Hotels as Costs Soar
- Ford (NYSE:F) May Lose Post Office Contract Under Trump
- Gelsinger Takes to X to Support Intel’s (NASDAQ:INTC) 18A Processes
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
